Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients

European Journal of Clinical Pharmacology

Volumn 62, Issue 10, 2006, Pages 877-880

  Kurzawski, Mateusz ^a   Gawrońska Szklarz, Barbara ^a   Wrześniewska, Joanna ^a   Siuda, Andrzej ^b   Starzyńska, Teresa ^a   Droździk, Marek ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Regional Hospital   (Poland)

Author keywords

CYP2C19; Genetic polymorphism; Helicobacter pylori; Peptic ulcer; Pharmacogenetics

Indexed keywords

AMOXICILLIN; CYTOCHROME P450 2C19; METRONIDAZOLE; PANTOPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIINFECTIVE AGENT; ANTIULCER AGENT; CYP2C19 PROTEIN, HUMAN; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

ADULT; AGED; ALLELE; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; DRUG COMBINATION; DRUG EFFECT; GENETICS; HAPLOTYPE; MICROBIOLOGY; MIDDLE AGED; RISK;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AGED, 80 AND OVER; ALLELES; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; DRUG THERAPY, COMBINATION; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; ODDS RATIO; PEPTIC ULCER; POLYMORPHISM, GENETIC; TREATMENT OUTCOME;

EID: 33749501237     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0183-2     Document Type: Article

References (16)

1. Andersson T, Regardh CG, Dahl-Puustinen ML, Bertilsson L (1990) Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 12:415-416. 3
2. Andersson T, Flockhart DA, Goldstein DB, Huang SM, Kroetz DL, Milos PM, Ratain MJ, Thummel K (2005) Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther 78:559-581
3. Boyanova L, Mentis A, Gubina M, Rozynek E, Gosciniak G, Kalenic S, Goral V, Kupcinskas L, Kantarceken B, Aydin A, Archimandritis A, Dzierzanowska D, Vcev A, Ivanova K, Marina M, Mitov I, Petrov P, Ozden A, Popova M (2002) The status of antimicrobial resistance of Helicobacter pylori in eastern Europe. Clin Microbiol Infect 8:388-396
4. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E (2001) Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 69:158-168
5. Furuta T, Shirai N, Watanabe F, Honda S, Takeuchi K, Iida T, Sato Y, Kajimura M, Futami H, Takayanagi S, Yamada M, Ohashi K, Ishizaki T, Hanai H (2002) Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 72:453-460
6. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T (2005) Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 20:153-167
7. Gawronska-Szklarz B, Wrzesniewska J, Starzynska T, Pawlik A, Safranow K, Ferenc K, Drozdzik M (2005) Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection. Eur J Clin Pharmacol 61:375-379
8. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI (1994) Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33:1743-1752
9. Goldstein JA, Blaisdell J (1996) Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol 272:210-218
10. Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering Jr RC (1989) Effect of varying pH on the susceptibility of Campylobacter Eliopoulos GM pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 8:888-889
11. Gustincich S, Manfioletti G, Del Sal G, Schneider C, Carninci P (1991) A fast method for high-quality genomic DNA extraction from whole human blood. Biotechniques 11:298-300, 302
12. Kupfer A, Preisig R (1984) Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26:753-759
13. Scott D, Weeks D, Melchers K, Sachs G (1998) The life and death of Helicobacter pylori. Gut 43 Suppl 1:S56-S60
14. Shimatani T, Inoue M, Kuroiwa T, Horikawa Y, Mieno H, Nakamura M (2003) Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H2-receptor antagonist. Aliment Pharmacol Ther 18:1149-1157
15. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103-113
16. Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T (1997) Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 283:434-442